Cancer research groups push emergency funding to restart clinical trials in infrastructure package

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A group of more than 50 cancer research-focused organizations are urging Congress to include $10 billion in emergency funding to restart cancer research and clinical trials at the National Institutes of Health stalled by the coronavirus pandemic.

In a letter sent to lawmakers, members of the One Voice Against Cancer coalition say without the additional resources in the forthcoming American Jobs Plan, promising research will languish and potentially be lost entirely.

“The pandemic’s impact on cancer research has been severe. Early shutdowns forced research to come to an abrupt halt, and restarting trials has required implementing new protocols, procuring personal protective equipment and sometimes restarting work altogether that otherwise could not be resumed,” Lisa Lacasse, president of the American Cancer Society Cancer Action Network, said in a statement. “The cost of these disruptions has been significant and threatens to jeopardize progress in the effort to reduce our country’s cancer burden for years to come.”

“Clinical trials are often the best and sometimes only course of treatment for patients in need of care. On behalf of all cancer patients, survivors and their families, we urge Congress to include this additional NIH funding in the American Jobs Plan and ensure medical research can keep moving forward without delay.”

Table of Contents

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login